# US 7,745,476 B2 · 1,3,5-trisubstituted 4,5-dihydro-1H-pyrazole derivatives having CB1-antagonistic activity

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 7,745,476 B2
- Document ID: US7745476B2
- Status: Granted
- Kind: B2
- Application number: 11/033,683
- Filed: 2005-01-13
- Published: 2005-08-04
- Granted: 2010-06-29
- Earliest claimed: 2004-01-30
- Assignees: Solvay Pharmaceuticals GmbH
- Inventors: Josephus H. M. Lange; Cornelis G. Kruse; Herman H. Van Stuivenberg
- Web page: https://patentgrep.com/patent/US7745476B2

## CPC

- C07D 231/06: having one double bond between ring members or between a ring member and a non-ring member
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)

## Abstract

The present invention relates to 1,3,5-trisubstituted 4,5-dihydro-1H-pyrazole derivatives as CB1 antagonists, to methods for the preparation of these compounds and to novel intermediates useful for the synthesis of said pyrazole derivatives. The invention also relates to the use of a compound disclosed herein for the manufacture of a medicament giving a beneficial effect. The compounds have the general formula (I) wherein the symbols have the meanings given in the specification.

## Claims

### Claim 1

A compound of formula (1), a tautomer, a stereoisomer, or an N-oxide thereof, or a salt or a hydrate of any of the foregoing:
wherein:
R1 and R2, which may be identical or different, are each chosen from
phenyls, thienyls and pyridyls, optionally substituted with 1, 2 or 3 substituents Y, which may be identical or different, chosen from branched or linear C1-3-alkyls and alkoxys, phenyls, hydroxys, chloro, bromo, fluoro, iodo, trifluoromethyl, trifluoromethylthio, trifluoromethoxy, methylsulfonyl, carboxyl, trifluoromethylsulfonyl, cyano, carbamoyl, sulfamoyl and acetyl, and
naphthyl;
X is chosen from (i) and (ii),
wherein:
R3 is chosen from hydrogen atoms and branched or linear C1-3 alkyl groups;
R4 is chosen from
branched or linear C1-8 alkyls and C3-8-cycloalkyl-C1-2-alkyl groups, branched or linear C1-8 alkoxys, C3-8 cycloalkyls, C5-10 bicycloalkyls, C6-10 tricycloalkyls, optionally comprising at least one heteroatom chosen from O, N, and S and optionally substituted with a group chosen from hydroxy groups, from 1 to 3 methyl groups, ethyl groups, and from 1 to 3 fluoro atoms,
phenoxy, benzyl, phenethyl and phenylpropyl groups, optionally substituted on the phenyl ring with 1, 2 or 3 substituents Y, which may be identical or different, chosen from branched or linear C1-3-alkyls and alkoxys, phenyls, hydroxys, chloro, bromo, fluoro, iodo, trifluoromethyl, trifluoromethylthio, trifluoromethoxy, methylsulfonyl, carboxyl, trifluoromethylsulfonyl, cyano, carbamoyl, sulfamoyl and acetyl,
pyridyl and thienyl groups, and
NR5R6 wherein:
R5 and R6, together with the nitrogen atom to which they are attached, form a saturated or unsaturated, monocyclic or bicyclic, heterocyclic group comprising from 4 to 10 ring atoms, wherein the heterocyclic group comprises one or two heteroatoms chosen from O, N, and S and wherein the heterocyclic group is optionally substituted with a group chosen from branched or linear C1-3 alkyls, phenyls, hydroxy, trifluoromethyl groups and fluoro atoms; or
R3and R4, together with the nitrogen atom to which they are attached, form a saturated or unsaturated, monocyclic or bicyclic, heterocyclic group comprising from 4 to 10 ring atoms, wherein the heterocyclic group comprises one or two heteroatoms chosen from O, N, and S and wherein the heterocyclic group is optionally substituted with a group chosen from branched or linear C1-3 alkyls, phenyls, hydroxy, trifluoromethyl groups and fluoro atoms;
R7 is chosen from
benzyl, phenyl, thienyl and pyridyl groups, optionally substituted on the aromatic ring with 1, 2, 3 or 4 substituents Y, which may be identical or different, chosen from branched or linear C1-3-alkyls and alkoxys, phenyls, hydroxys, chloro, bromo, fluoro, iodo, trifluoromethyl, trifluoromethylthio, trifluoromethoxy, methylsulfonyl, carboxyl, trifluoromethylsulfonyl, cyano, carbamoyl, sulfamoyl and acetyl,
C1-8 branched or linear alkyls, C3-8 alkenyls, C3-10 cycloalkyls, C5-10 bicycloalkyls, C6-10 tricycloalkyls and C5-8 cycloalkenyls,
naphthyl,
amino groups, and
C1-8 dialkylamino groups, C1-8 monoalkylamino groups and saturated or unsaturated, monocyclic or bicyclic, heterocyclic groups having 4 to 10 ring atoms, wherein the heterocyclic group comprises 1 or 2 nitrogen atoms and wherein the heterocyclic group optionally comprises 1heteroatom chosen from O and S and wherein the heterocyclic group is optionally substituted with anentity chosen from branched or linear C1-3 alkyls, phenyls, hydroxys, trifluoromethyls and fluoro atoms;
R8 is chosen from hydrogen atoms and branched or linear C1-3 alkyls;
R9 is chosen from
hydrogen atoms and branched or linear C1-8 alkyls, C3-8 cycloalkyls and C2-10 heteroalkyls, optionally substituted with a group chosen from keto groups, trifluoromethyl groups and fluoro atoms,
amino, hydroxy, phenoxy and benzyloxy groups
branched or linear C1-8 alkoxy groups, optionally substituted with an entity chosen from hydroxy groups, trifluoromethyl groups and fluoro atoms,
phenyl, benzyl, pyridyl, thienyl, pyridylmethyl and phenethyl groups wherein the aromatic rings are optionally substituted with 1, 2 or 3 of the substituents Y, which may be identical or different, chosen from branched or linear C1-3-alkyls and alkoxys, phenyls, hydroxys, chloro, bromo, fluoro, iodo, trifluoromethyl, trifluoromethylthio, trifluoromethoxy, methylsulfonyl, carboxyl, trifluoromethylsulfonyl, cyano, carbamoyl, sulfamoyl and acetyl, and
NR10R11 with the proviso when R8 is chosen from a hydrogen atom or a methyl group, and wherein
R10 and R11, which may be identical or different, are each chosen from C1-4 alkyls and C2-4 trifluoroalkyls or
R10 and R11, together with the nitrogen atom to which they are bonded, form a saturated or unsaturated heterocyclic group comprising from 4 to 8 ring atoms wherein the heterocyclic group comprises one or two atoms chosen from O, N, and S, and the heterocyclic group is optionally substituted with C1-2 alkyl groups; or
R8 and R9, together with the nitrogen atom to which they are bonded, form a saturated or unsaturated, monocyclic or bicyclic heterocyclic group comprising from 4 to 10 ring atoms, wherein the heterocyclic group comprises one or two atoms chosen from O, N, and S, keto groups and —SO2— groups, wherein the heterocyclic group is optionally substituted with C1-2 alkyls, hydroxys, phenyls, methylaminos, dimethylaminos, azetidinyls, pyrrolidinyls, piperidinyls and hexahydro-1H-azepinyls.

### Claim 2 (depends on 1)

The compound according to claim 1, wherein:
R1 and R2, which may be identical or different, are each chosen from
phenyls, optionally substituted with 1, 2 or 3 substituents Y, which may be identical or different, chosen from branched or linear C1-3-alkyls and alkoxys, phenyls, hydroxys, chloro, bromo, fluoro, iodo, trifluoromethyl, trifluoromethylthio, trifluoromethoxy, methylsulfonyl, carboxyl, trifluoromethylsulfonyl, cyano, carbamoyl, sulfamoyl and acetyl, and
naphthyl;
R3 comprises a hydrogen atom;
R4 is chosen from
branched or linear C1-8 alkyls, branched or linear C1-8 alkoxys, and C3-8 cycloalkyls, optionally substituted with at least one group chosen from hydroxy groups, from 1 to 3 methyl groups, an ethyl group, and from 1 to 3 fluoro atoms,
phenoxy, -pyridyl and thienyl groups, and
NR5R6 wherein:
R5 and R6, together with the nitrogen atom to which they are attached, form a saturated or unsaturated, monocyclic or bicyclic, heterocyclic group comprising from 4 to 10 ring atoms, wherein the heterocyclic group comprises one or two heteroatoms chosen from O, N, and S; or
R3 and R4, together with the nitrogen atom to which they are attached, form a saturated or unsaturated, monocyclic or bicyclic, heterocyclic group comprising from 4 to 10 ring atoms, wherein the heterocyclic group comprises one or two heteroatoms chosen from O, N, and S and wherein the heterocyclic group is optionally substituted with a group chosen from methyl groups, hydroxy groups, trifluoromethyl groups and fluoro atoms
R7 is chosen from
phenyl groups, optionally substituted on the aromatic ring with 1, 2, 3 or 4 substituents Y, which may be identical or different, chosen from branched or linear C1-3-alkyls and alkoxys, phenyls, hydroxys, chloro, bromo, fluoro, iodo, trifluoromethyl, trifluoromethylthio, trifluoromethoxy, methylsulfonyl, carboxyl, trifluoromethylsulfonyl, cyano, carbamoyl, sulfamoyl and acetyl,
C1-8 branched or linear alkyls, C3-10 cycloalkyls, and C5-10 bicycloalkyls,
naphthyl,
amino groups, and
C1-8 dialkylamino groups, C1-8 monoalkylamino groups and saturated or unsaturated, monocyclic or bicyclic, heterocyclic groups having from 4 to 10 ring atoms, wherein the heterocyclic group comprises 1 or 2 nitrogen atoms and wherein the heterocyclic group optionally comprises 1heteroatom chosen from O and S and wherein the heterocyclic group is optionally substituted with branched or linear C1-3 alkyls and hydroxys;
R8 is chosen from hydrogen atoms and branched or linear C1-3 alkyls;
R9 is chosen from
hydrogen atoms and branched or linear C1-4 alkyls or C3-8 cycloalkyls, optionally substituted with a group chosen from trifluoromethyl groups and fluoro atoms,
amino, hydroxy, phenoxy and benzyloxy groups,
branched or linear C1-8 alkoxy groups,
phenyl groups, wherein the aromatic rings are optionally substituted with 1, 2 or 3 of the substituents Y, which may be identical or different, chosen from branched or linear C1-3-alkyls and alkoxys, phenyls, hydroxys, chloro, bromo, fluoro, iodo, trifluoromethyl, trifluoromethylthio, trifluoromethoxy, methylsulfonyl, carboxyl, trifluoromethylsulfonyl, cyano, carbamoyl, sulfamoyl and acetyl, and
NR10R11 with the proviso when R8 is chosen from a hydrogen atom or a methyl group, and wherein
R10 and R11, which may be identical or different, are each chosen from C1-4 alkyls and C2-4 trifluoroalkyls or
R10 and R11, together with the nitrogen atom to which they are bonded, form a saturated or unsaturated heterocyclic group comprising from 4 to 8 ring atoms wherein the heterocyclic group comprises one or two atoms chosen from O, N, and S; or
R8 and R9, together with the nitrogen atom to which they are bonded, form a saturated or unsaturated, monocyclic or bicyclic heterocyclic group comprising from 4 to 10 ring atoms, wherein the heterocyclic group comprises one or two atoms chosen from O, N, and S, keto groups and —SO2— groups.

### Claim 3 (depends on 1)

The compound according to claim 1, wherein the formula (1) compound is chosen from:
N-(piperidin-1-yl)-1-(4-chlorophenyl)-5-phenyl-4,5-dihydro-(1H)-pyrazole-3-carboxamide,
N-(Piperidin-1-yl)-5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4,5-dihydro-(1H)-pyrazole-3-carboxamide,
N-(Piperidin-1-yl)-1-(2,4-dichlorophenyl)-5-phenyl-4,5-dihydro-(1H)-pyrazole-3-carboxamide,
N-(Cyclohexyl)-1-(2,4-dichlorophenyl)-5-phenyl-4,5-dihydro-(1H)-pyrazole-3-carboxamide,
N-[(4-fluorophenyl)sulfonyl]-1-(4-chlorophenyl)-5-phenyl-4,5-dihydro-(1H)-pyrazole-3-carboxamidine,
N-[(4-fluorophenyl)sulfonyl]-1-(2,4-dichlorophenyl)-5-phenyl-4,5-dihydro-(1H)-pyrazole-3-carboxamidine,
N-[(4-chlorophenyl)sulfonyl]-N′-methyl-1-(4-chlorophenyl)-5-phenyl-4,5-dihydro-(1H)-pyrazole-3-carboxamidine,
N-[(4-Chlorophenyl)sulfonyl]-N′-methyl-1-(2,4-dichlorophenyl)-5-phenyl-4,5-dihydro-(1H)-pyrazole-3-carboxamidine,
N-{[(4-Trifluoromethyl)phenyl]sulfonyl}-N′-methyl-1-(2, 4-dichlorophenyl)-5-phenyl-4,5-dihydro-(1H)-pyrazole-3-carboxamidine,
N-[(piperidin-1-yl)sulfonyl]-N′-methyl-1-(4-chlorophenyl)-5-phenyl-4,5-dihydro-(1H)-pyrazole-3-carboxamidine, and
N-[(Morpholin-4-yl)sulfonyl]-N′-methyl-1-(2,4-dichlorophenyl)-5-phenyl-4,5-dihydro-(1H)-pyrazole-3-carboxamidine.

### Claim 4

A pharmaceutical composition comprising:
at least one pharmaceutically acceptable carrier, at least one pharmaceutically acceptable auxiliary substance or a combination thereof, and
an effective amount of at least one compound of formula (1), a tautomer, a stereoisomer, or an N-oxide thereof, or a salt or a hydrate of any of the foregoing:
wherein:
R1 and R2, which may be identical or different, are each chosen from
phenyls, thienyls and pyridyls, optionally substituted with 1, 2 or 3 substituents Y, which may be identical or different, chosen from branched or linear C1-3-alkyls and alkoxys, phenyls, hydroxys, chloro, bromo, fluoro, iodo, trifluoromethyl, trifluoromethylthio, trifluoromethoxy, methylsulfonyl, carboxyl, trifluoromethylsulfonyl, cyano, carbamoyl, sulfamoyl and acetyl, and
naphthyl;
X is chosen from (i) and (ii),
wherein:
R3 is chosen from hydrogen atoms and branched or linear C1-3 alkyl groups;
R4 is chosen from
branched or linear C1-8 alkyls and C3-8-cycloalkyl-C1-2-alkyl groups, branched or linear C1-8 alkoxys, C3-8 cycloalkyls, C5-10 bicycloalkyls, C6-10 tricycloalkyls, optionally comprising at least one heteroatom chosen from O, N, and S and optionally substituted with a group chosen from hydroxy groups, from 1 to 3 methyl groups, ethyl groups, and from 1 to 3 fluoro atoms,
phenoxy, benzyl, phenethyl and phenylpropyl groups, optionally substituted on the phenyl ring with 1, 2 or 3 substituents Y, which may be identical or different, chosen from branched or linear C1-3-alkyls and alkoxys, phenyls, hydroxys, chloro, bromo, fluoro, iodo, trifluoromethyl, trifluoromethylthio, trifluoromethoxy, methylsulfonyl, carboxyl, trifluoromethylsulfonyl, cyano, carbamoyl, sulfamoyl and acetyl,
pyridyl and thienyl groups, and
NR5R6 wherein:
R5 and R6, together with the nitrogen atom to which they are attached, form a saturated or unsaturated, monocyclic or bicyclic, heterocyclic group comprising from 4 to 10 ring atoms, wherein the heterocyclic group comprises one or two heteroatoms chosen from O, N, and S and wherein the heterocyclic group is optionally substituted with a group chosen from branched or linear C1-3 alkyls, phenyls, hydroxy, trifluoromethyl groups and fluoro atoms; or
R3 and R4, together with the nitrogen atom to which they are attached, form a saturated or unsaturated, monocyclic or bicyclic, heterocyclic group comprising from 4 to 10 ring atoms, wherein the heterocyclic group comprises one or two heteroatoms chosen from O, N, and S and wherein the heterocyclic group is optionally substituted with a group chosen from branched or linear C1-3 alkyls, phenyls, hydroxy, trifluoromethyl groups and fluoro atoms
R7 is chosen from
benzyl, phenyl, thienyl and pyridyl groups, optionally substituted on the aromatic ring with 1, 2, 3 or 4 substituents Y, which may be identical or different, chosen from branched or linear C1-3-alkyls and alkoxys, phenyls, hydroxys, chloro, bromo, fluoro, iodo, trifluoromethyl, trifluoromethylthio, trifluoromethoxy, methylsulfonyl, carboxyl, trifluoromethylsulfonyl, cyano, carbamoyl, sulfamoyl, and acetyl,
C1-8 branched or linear alkyls, C3-8 alkenyls, C3-10 cycloalkyls, C5-10 bicycloalkyls, C6-10 tricycloalkyls and C5-8 cycloalkenyls,
naphthyl,
amino groups, and
C1-8 dialkylamino groups, C1-8 monoalkylamino groups and saturated or unsaturated, monocyclic or bicyclic, heterocyclic groups having 4 to 10 ring atoms, wherein the heterocyclic group comprises 1 or 2 nitrogen atoms and wherein the heterocyclic group optionally comprises 1heteroatom chosen from O and S and wherein the heterocyclic group is optionally substituted with anentity chosen from branched or linear C1-3 alkyls, phenyls, hydroxys, trifluoromethyls and fluoro atoms;
R8 is chosen from hydrogen atoms and branched or linear C1-3 alkyls;
R9 is chosen from
hydrogen atoms and branched or linear C1-8 alkyls, C3-8 cycloalkyls and C2-10 heteroalkyls, optionally substituted with a group chosen from keto groups, trifluoromethyl groups and fluoro atoms,
amino, hydroxy, phenoxy and benzyloxy groups
branched or linear C1-8 alkoxy groups, optionally substituted with an entity chosen from hydroxy groups, trifluoromethyl groups and fluoro atoms,
phenyl, benzyl, pyridyl, thienyl, pyridylmethyl and phenethyl groups wherein the aromatic rings are optionally substituted with 1, 2 or 3 of the substituents Y, which may be identical or different, chosen from branched or linear C1-3-alkyls and alkoxys, phenyls, hydroxys, chloro, bromo, fluoro, iodo, trifluoromethyl, trifluoromethylthio, trifluoromethoxy, methylsulfonyl, carboxyl, trifluoromethylsulfonyl, cyano, carbamoyl, sulfamoyl and acetyl, and
NR10R11 with the proviso when R8 is chosen from a hydrogen atom or a methyl group, and wherein
R10 and R11, which may be identical or different, are each chosen from C1-4 alkyls and C2-4 trifluoroalkyls or
R10 and R11, together with the nitrogen atom to which they are bonded, form a saturated or unsaturated heterocyclic group comprising from 4 to 8 ring atoms wherein the heterocyclic group comprises one or two atoms chosen from O, N, and S, and the heterocyclic group is optionally substituted with C1-2 alkyl groups; or
R8 and R9, together with the nitrogen atom to which they are bonded, form a saturated or unsaturated, monocyclic or bicyclic heterocyclic group comprising from 4 to 10 ring atoms, wherein the heterocyclic group comprises one or two atoms chosen from O, N, and S, keto groups and —SO2— groups, wherein the heterocyclic group is optionally substituted with C1-2 alkyls, hydroxys, phenyls, methylaminos, dimethylaminos, azetidinyls, pyrrolidinyls, piperidinyls and hexahydro-1H-azepinyls.

### Claim 5 (depends on 4)

The pharmaceutical composition of claim 4, wherein:
R1 and R2, which may be identical or different, are each chosen from
phenyls, optionally substituted with 1, 2 or 3 substituents Y, which may be identical or different, chosen from branched or linear C1-3-alkyls and alkoxys, phenyls, hydroxys, chloro, bromo, fluoro, iodo, trifluoromethyl, trifluoromethylthio, trifluoromethoxy, methylsulfonyl, carboxyl, trifluoromethylsulfonyl, cyano, carbamoyl, sulfamoyl and acetyl, and
naphthyl;
R3 comprises a hydrogen atom;
R4 is chosen from
branched or linear C1-8 alkyls, branched or linear C1-8 alkoxys, and C3-8 cycloalkyls, optionally substituted with at least one group chosen from hydroxy groups, from 1 to 3 methyl groups, an ethyl group, and from 1 to 3 fluoro atoms,
phenoxy, -pyridyl and thienyl groups, and
NR5R6 wherein:
R5 and R6, together with the nitrogen atom to which they are attached, form a saturated or unsaturated, monocyclic or bicyclic, heterocyclic group comprising from 4 to 10 ring atoms, wherein the heterocyclic group comprises one or two heteroatoms chosen from O, N, and S; or
R3 and R4, together with the nitrogen atom to which they are attached, form a saturated or unsaturated, monocyclic or bicyclic, heterocyclic group comprising from 4 to 10 ring atoms, wherein the heterocyclic group comprises one or two heteroatoms chosen from O, N, and S and wherein the heterocyclic group is optionally substituted with a group chosen from methyl groups, hydroxy groups, trifluoromethyl groups and fluoro atoms
R7 is chosen from
phenyl groups, optionally substituted on the aromatic ring with 1, 2, 3 or 4 substituents Y, which may be identical or different, chosen from branched or linear C1-3-alkyls and alkoxys, phenyls, hydroxys, chloro, bromo, fluoro, iodo, trifluoromethyl, trifluoromethylthio, trifluoromethoxy, methylsulfonyl, carboxyl, trifluoromethylsulfonyl, cyano, carbamoyl, sulfamoyl and acetyl,
C1-8 branched or linear alkyls, C3-10 cycloalkyls, and C5-10 bicycloalkyls,
naphthyl,
amino groups, and
C1-8dialkylamino groups, C1-8 monoalkylamino groups and saturated or unsaturated, monocyclic or bicyclic, heterocyclic groups having from 4 to 10 ring atoms, wherein the heterocyclic group comprises 1 or 2 nitrogen atoms and wherein the heterocyclic group optionally comprises 1 heteroatom chosen from O and S and wherein the heterocyclic group is optionally substituted with branched or linear C1-3 alkyls and hydroxys;
R8 is chosen from hydrogen atoms and branched or linear C1-3 alkyls;
R9 is chosen from
hydrogen atoms and branched or linear C1-4 alkyls or C3-8 cycloalkyls, optionally substituted with a group chosen from trifluoromethyl groups and fluoro atoms,
amino, hydroxy, phenoxy and benzyloxy groups,
branched or linear C1-8 alkoxy groups,
phenyl groups, wherein the aromatic rings are optionally substituted with 1, 2 or 3 of the substituents Y, which may be identical or different, chosen from branched or linear C1-3-alkyls and alkoxys, phenyls, hydroxys, chloro, bromo, fluoro, iodo, trifluoromethyl, trifluoromethylthio, trifluoromethoxy, methylsulfonyl, carboxyl, trifluoromethylsulfonyl, cyano, carbamoyl, sulfamoyl and acetyl, and
NR10R11 with the proviso when R8 is chosen from a hydrogen atom or a methyl group, and wherein
R10 and R11, which may be identical or different, are each chosen from C1-4 alkyls and C2-4 trifluoroalkyls or
R10 and R11, together with the nitrogen atom to which they are bonded, form a saturated or unsaturated heterocyclic group comprising from 4 to 8 ring atoms wherein the heterocyclic group comprises one or two atoms chosen from O, N, and S; or
R8 and R9, together with the nitrogen atom to which they are bonded, form a saturated or unsaturated, monocyclic or bicyclic heterocyclic group comprising from 4 to 10 ring atoms, wherein the heterocyclic group comprises one or two atoms chosen from O, N, and S, keto groups and —SO2— groups.

### Claim 6 (depends on 4)

The pharmaceutical composition of claim 4, wherein the formula (1) compound is chosen from
N-(piperidin-1-yl)-1-(4-chlorophenyl)-5-phenyl-4,5-dihydro-(1H)-pyrazole-3-carboxamide,
N-(Piperidin-1-yl)-5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4,5-dihydro-(1H)-pyrazole-3-carboxamide,
N-(Piperidin-1-yl)-1-(2,4-dichlorophenyl)-5-phenyl-4,5-dihydro-(1H)-pyrazole-3-carboxamide,
N-(Cyclohexyl)-1-(2,4-dichlorophenyl)-5-phenyl-4,5-dihydro-(1H)-pyrazole-3-carboxamide,
N-[(4-fluorophenyl)sulfonyl]-1-(4-chlorophenyl)-5-phenyl-4,5-dihydro-(1H)-pyrazole-3-carboxamidine,
N-[(4-fluorophenyl)sulfonyl]-1-(2,4-dichlorophenyl)-5-phenyl-4,5-dihydro-(1H)-pyrazole-3-carboxamidine,
N-[(4-chlorophenyl)sulfonyl]-N′-methyl-1-(4-chlorophenyl)-5-phenyl-4,5-dihydro-(1H)-pyrazole-3-carboxamidine,
N-[(4-Chlorophenyl)sulfonyl]-N′-methyl-1-(2,4-dichlorophenyl)-5-phenyl-4,5-dihydro-(1H)-pyrazole-3-carboxamidine,
N-{[(4-Trifluoromethyl)phenyl]sulfonyl}-N′-methyl-1-(2,4-dichlorophenyl)-5-phenyl-4,5-dihydro-(1H)-pyrazole-3-carboxamidine,
N-[(piperidin-1-yl)sulfonyl]-N′-methyl-1-(4-chlorophenyl)-5-phenyl-4,5-dihydro-(1H)-pyrazole-3-carboxamidine, and
N-[(Morpholin-4-yl)sulfonyl]-N′-methyl-1-(2,4-dichlorophenyl)-5-phenyl-4,5-dihydro-(1H)-pyrazole-3-carboxamidine.

### Claim 7

A compound of formula (X), a tautomer thereof, or a salt thereof of any of the foregoing:
wherein R1 and R2, which may be identical or different, are each chosen from
phenyls, thienyls and pyridyls, optionally substituted with 1, 2 or 3 substituents Y, which may be identical or different, chosen from branched or linear C1-3-alkyls and alkoxys, phenyls, hydroxys, chloro, bromo, fluoro, iodo, trifluoromethyl, trifluoromethylthio, trifluoromethoxy, methylsulfonyl, carboxyl, trifluoromethylsulfonyl, cyano, carbamoyl, sulfamoyl and acetyl, and
naphthyl.

### Claim 8

The compounds of formula (XI)
wherein R1 and R2, which may be identical or different, are each chosen from
phenyls, thienyls and pyridyls, optionally substituted with 1, 2 or 3 substituents Y, which may be identical or different, chosen from branched or linear C1-3-alkyls and alkoxys, phenyls, hydroxys, chloro, bromo, fluoro, iodo, trifluoromethyl, trifluoromethylthio, trifluoromethoxy, methylsulfonyl, carboxyl, trifluoromethylsulfonyl, cyano, carbamoyl, sulfamoyl and acetyl, and
naphthyl; and
R7 is chosen from
benzyl, phenyl, thienyl and pyridyl groups, optionally substituted on the aromatic ring with 1, 2, 3 or 4 substituents Y, which may be identical or different, chosen from branched or linear C1-3-alkyls and alkoxys, phenyls, hydroxys, chloro, bromo, fluoro, iodo, trifluoromethyl, trifluoromethylthio, trifluoromethoxy, methylsulfonyl, carboxyl, trifluoromethylsulfonyl, cyano, carbamoyl, sulfamoyl and acetyl,
C1-8 branched or linear alkyls, C3-8 alkenyls, C3-10 cycloalkyls, C5-10 bicycloalkyls, C6-10 tricycloalkyls and C5-8 cycloalkenyls,
naphthyl,
amino groups, and
C1-8 dialkylamino groups, C1-8 monoalkylamino groups and saturated or unsaturated, monocyclic or bicyclic, heterocyclic groups having 4 to 10 ring atoms, wherein the heterocyclic group comprises 1 or 2 nitrogen atoms and wherein the heterocyclic group optionally comprises 1 heteroatom chosen from O and S and wherein the heterocyclic group is optionally substituted with anentity chosen from branched or linear C1-3 alkyls, phenyls, hydroxys, trifluoromethyls and fluoro atoms.

### Claim 9

The compounds of formula (XII)
wherein R1 and R2, which may be identical or different, are each chosen from
phenyls, thienyls and pyridyls, optionally substituted with 1, 2 or 3 substituents Y, which may be identical or different, chosen from branched or linear C1-3-alkyls and alkoxys, phenyls, hydroxys, chloro, bromo, fluoro, iodo, trifluoromethyl, trifluoromethylthio, trifluoromethoxy, methylsulfonyl, carboxyl, trifluoromethylsulfonyl, cyano, carbamoyl, sulfamoyl and acetyl, and
naphthyl; and
R7 is chosen from
benzyl, phenyl, thienyl and pyridyl groups, optionally substituted on the aromatic ring with 1, 2, 3 or 4 substituents Y, which may be identical or different, chosen from branched or linear C1-3-alkyls and alkoxys, phenyls, hydroxys, chloro, bromo, fluoro, iodo, trifluoromethyl, trifluoromethylthio, trifluoromethoxy, methylsulfonyl, carboxyl, trifluoromethylsulfonyl, cyano, carbamoyl, sulfamoyl and acetyl,
C1-8 branched or linear alkyls, C3-8 alkenyls, C3-10 cycloalkyls, C5-10 bicycloalkyls, C6-10 tricycloalkyls and C5-8 cycloalkenyls,
naphthyl,
amino groups, and
C1-8 dialkylamino groups, C1-8 monoalkylamino groups and saturated or unsaturated, monocyclic or bicyclic, heterocyclic groups having 4 to 10 ring atoms, wherein the heterocyclic group comprises 1 or 2 nitrogen atoms and wherein the heterocyclic group optionally comprises 1 heteroatom chosen from O and S and wherein the heterocyclic group is optionally substituted with anentity chosen from branched or linear C1-3 alkyls, phenyls, hydroxys, trifluoromethyls and fluoro atoms; and
wherein Z is chosen from Cl and Br atoms.

### Claim 10

A method for preparing a medicament, comprising: combining an effective amount of at least one compound of formula (1), a tautomer, a stereoisomer, or N-oxide thereof, or a salt or hydrate of any of the foregoing:
wherein:
R1 and R2, which may be identical or different, are each chosen from
phenyls, thienyls and pyridyls, optionally substituted with 1, 2 or 3 substituents Y, which may be identical or different, chosen from branched or linear C1-3-alkyls and alkoxys, phenyls, hydroxys, chloro, bromo, fluoro, iodo, trifluoromethyl, trifluoromethylthio, trifluoromethoxy, methylsulfonyl, carboxyl, trifluoromethylsulfonyl, cyano, carbamoyl, sulfamoyl and acetyl, and
naphthyl;
X is chosen from (i) and (ii),
wherein:
R3 is chosen from hydrogen atoms and branched or linear C1-3 alkyl groups;
R4 is chosen from
branched or linear C1-8 alkyls and C3-8-cycloalkyl-C1-2-alkyl groups, branched or linear C1-8 alkoxys, C3-8 cycloalkyls, C5-10 bicycloalkyls, C6-10 tricycloalkyls, optionally comprising at least one heteroatom chosen from O, N, and S and optionally substituted with a group chosen from hydroxy groups, from 1 to 3 methyl groups, ethyl groups, and from 1 to 3 fluoro atoms,
phenoxy, benzyl, phenethyl and phenylpropyl groups, optionally substituted on the phenyl ring with 1, 2 or 3 substituents Y, which may be identical or different, chosen from branched or linear C1-3-alkyls and alkoxys, phenyls, hydroxys, chloro, bromo, fluoro, iodo, trifluoromethyl, trifluoromethylthio, trifluoromethoxy, methylsulfonyl, carboxyl, trifluoromethylsulfonyl, cyano, carbamoyl, sulfamoyl and acetyl,
pyridyl and thienyl groups, and
NR5R6 wherein:
R5 and R6, together with the nitrogen atom to which they are attached, form a saturated or unsaturated, monocyclic or bicyclic, heterocyclic group comprising from 4 to 10 ring atoms, wherein the heterocyclic group comprises one or two heteroatoms chosen from O, N, and S and wherein the heterocyclic group is optionally substituted with a group chosen from branched or linear C1-3 alkyls, phenyls, hydroxy, trifluoromethyl groups and fluoro atoms; or
R3 and R4, together with the nitrogen atom to which they are attached, form a saturated or unsaturated, monocyclic or bicyclic, heterocyclic group comprising from 4 to 10 ring atoms, wherein the heterocyclic group comprises one or two heteroatoms chosen from O, N, and S and wherein the heterocyclic group is optionally substituted with a group chosen from branched or linear C1-3 alkyls, phenyls, hydroxy, trifluoromethyl groups and fluoro atoms;
R7 is chosen from
benzyl, phenyl, thienyl and pyridyl groups, optionally substituted on the aromatic ring with 1, 2, 3 or 4 substituents Y, which may be identical or different, chosen from branched or linear C1-3-alkyls and alkoxys, phenyls, hydroxys, chloro, bromo, fluoro, iodo, trifluoromethyl, trifluoromethylthio, trifluoromethoxy, methylsulfonyl, carboxyl, trifluoromethylsulfonyl, cyano, carbamoyl, sulfamoyl and acetyl,
C1-8 branched or linear alkyls, C3-8 alkenyls, C3-10 cycloalkyls, C5-10 bicycloalkyls, C6-10 tricycloalkyls and C5-8 cycloalkenyls,
naphthyl,
amino groups, and
C1-8 dialkylamino groups, C1-8 monoalkylamino groups and saturated or unsaturated, monocyclic or bicyclic, heterocyclic groups having 4 to 10 ring atoms, wherein the heterocyclic group comprises 1 or 2 nitrogen atoms and wherein the heterocyclic group optionally comprises 1heteroatom chosen from O and S and wherein the heterocyclic group is optionally substituted with anentity chosen from branched or linear C1-3 alkyls, phenyls, hydroxys, trifluoromethyls and fluoro atoms;
R8 is chosen from hydrogen atoms and branched or linear C1-3 alkyls;
R9 is chosen from
hydrogen atoms and branched or linear C1-8 alkyls, C3-8 cycloalkyls and C2-10 heteroalkyls, optionally substituted with a group chosen from keto groups, trifluoromethyl groups and fluoro atoms,
amino, hydroxy, phenoxy and benzyloxy groups
branched or linear C1-8 alkoxy groups, optionally substituted with an entity chosen from hydroxy groups, trifluoromethyl groups and fluoro atoms,
phenyl, benzyl, pyridyl, thienyl, pyridylmethyl and phenethyl groups wherein the aromatic rings are optionally substituted with 1, 2 or 3 of the substituents Y, which may be identical or different, chosen from branched or linear C1-3-alkyls and alkoxys, phenyls, hydroxys, chloro, bromo, fluoro, iodo, trifluoromethyl, trifluoromethylthio, trifluoromethoxy, methylsulfonyl, carboxyl, trifluoromethylsulfonyl, cyano, carbamoyl, sulfamoyl and acetyl, and
NR10R11 with the proviso when R8 is chosen from a hydrogen atom or a methyl group, and wherein
R10 and R11, which may be identical or different, are each chosen from C1-4 alkyls and C2-4 trifluoroalkyls or
R10 and R11, together with the nitrogen atom to which they are bonded, form a saturated or unsaturated heterocyclic group comprising from 4 to 8 ring atoms wherein the heterocyclic group comprises one or two atoms chosen from O, N, and S, and the heterocyclic group is optionally substituted with C1-2 alkyl groups; or
R8 and R9, together with the nitrogen atom to which they are bonded, form a saturated or unsaturated, monocyclic or bicyclic heterocyclic group comprising from 4 to 10 ring atoms, wherein the heterocyclic group comprises one or two atoms chosen from O, N, and S, keto groups and —SO2— groups, wherein the heterocyclic group is optionally substituted with C1-2 alkyls, hydroxys, phenyls, methylaminos, dimethylaminos, azetidinyls, pyrrolidinyls, piperidinyls and hexahydro-1H-azepinyls; and at least one pharmaceutically acceptable carrier, at least one pharmaceutically acceptable auxiliary substance, or a combination thereof.

### Claim 11 (depends on 10)

The method of claim 10, wherein:
R1 and R2, which may be identical or different, are each chosen from
phenyls, optionally substituted with 1, 2 or 3 substituents Y, which may be identical or different, chosen from branched or linear C1-3-alkyls and alkoxys, phenyls, hydroxys, chloro, bromo, fluoro, iodo, trifluoromethyl, trifluoromethylthio, trifluoromethoxy, methylsulfonyl, carboxyl, trifluoromethylsulfonyl, cyano, carbamoyl, sulfamoyl and acetyl, and
naphthyl;
R3 comprises a hydrogen atom;
R4 is chosen from
branched or linear C1-8 alkyls, branched or linear C1-8 alkoxys, and C3-8 cycloalkyls, optionally substituted with at least one group chosen from hydroxy groups, from 1 to 3 methyl groups, an ethyl group, and from 1 to 3 fluoro atoms,
phenoxy, -pyridyl and thienyl groups, and
NR5R6 wherein:
R5 and R6, together with the nitrogen atom to which they are attached, form a saturated or unsaturated, monocyclic or bicyclic, heterocyclic group comprising from 4 to 10 ring atoms, wherein the heterocyclic group comprises one or two heteroatoms chosen from O, N, and S; or
R3 and R4, together with the nitrogen atom to which they are attached, form a saturated or unsaturated, monocyclic or bicyclic, heterocyclic group comprising from 4 to 10 ring atoms, wherein the heterocyclic group comprises one or two heteroatoms chosen from O, N, and S and wherein the heterocyclic group is optionally substituted with a group chosen from methyl groups, hydroxy groups, trifluoromethyl groups and fluoro atoms;
R7 is chosen from
phenyl groups, optionally substituted on the aromatic ring with 1, 2, 3 or 4 substituents Y, which may be identical or different, chosen from branched or linear C1-3-alkyls and alkoxys, phenyls, hydroxys, chloro, bromo, fluoro, iodo, trifluoromethyl, trifluoromethylthio, trifluoromethoxy, methylsulfonyl, carboxyl, trifluoromethylsulfonyl, cyano, carbamoyl, sulfamoyl and acetyl,
C1-8 branched or linear alkyls, C3-10 cycloalkyls, and C5-10 bicycloalkyls,
naphthyl,
amino groups, and
C1-8 dialkylamino groups, C1-8 monoalkylamino groups and saturated or unsaturated, monocyclic or bicyclic, heterocyclic groups having from 4 to 10 ring atoms, wherein the heterocyclic group comprises 1 or 2 nitrogen atoms and wherein the heterocyclic group optionally comprises 1 heteroatom chosen from O and S and wherein the heterocyclic group is optionally substituted with branched or linear C1-3 alkyls and hydroxys;
R8 is chosen from hydrogen atoms and branched or linear C1-3 alkyls;
R9 is chosen from
hydrogen atoms and branched or linear C1-4 alkyls or C3-8 cycloalkyls, optionally substituted with a group chosen from trifluoromethyl groups and fluoro atoms,
amino, hydroxy, phenoxy and benzyloxy groups,
branched or linear C1-8 alkoxy groups,
phenyl groups wherein the aromatic rings are optionally substituted with 1, 2 or 3 of the substituents Y, which may be identical or different, chosen from branched or linear C1-3-alkyls and alkoxys, phenyls, hydroxys, chloro, bromo, fluoro, iodo, trifluoromethyl, trifluoromethylthio, trifluoromethoxy, methylsulfonyl, carboxyl, trifluoromethylsulfonyl, cyano, carbamoyl, sulfamoyl and acetyl, and
NR10R11 with the proviso when R8 is chosen from a hydrogen atom or a methyl group, and wherein
R10 and R11, which may be identical or different, are each chosen from C1-4 alkyls and C2-4 trifluoroalkyls or
R10 and R11, together with the nitrogen atom to which they are bonded, form a saturated or unsaturated heterocyclic group comprising from 4 to 8 ring atoms wherein the heterocyclic group comprises one or two atoms chosen from O, N, and S; or
R8 and R9, together with the nitrogen atom to which they are bonded, form a saturated or unsaturated, monocyclic or bicyclic heterocyclic group comprising from 4 to 10 ring atoms, wherein the heterocyclic group comprises one or two atoms chosen from O, N, and S, keto groups and —SO2— groups.

### Claim 12 (depends on 10)

The method of claim 10, wherein the formula (1) compound is chosen from:
N-(piperidin-1-yl)-1-(4-chlorophenyl)-5-phenyl-4,5-dihydro-(1H)-pyrazole-3-carboxamide,
N-(Piperidin-1-yl)-5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4,5-dihydro-(1H)-pyrazole-3-carboxamide,
N-(Piperidin-1-yl)-1-(2,4-dichlorophenyl)-5-phenyl-4,5-dihydro-(1H)-pyrazole-3-carboxamide,
N-(Cyclohexyl)-1-(2,4-dichlorophenyl)-5-phenyl-4,5-dihydro-(1H)-pyrazole-3-carboxamide,
N-[(4-fluorophenyl)sulfonyl]-1-(4-chlorophenyl)-5-phenyl-4,5-dihydro-(1H)-pyrazole-3-carboxamidine,
N-[(4-fluorophenyl)sulfonyl]-1-(2,4-dichlorophenyl)-5-phenyl-4,5-dihydro-(1H)-pyrazole-3-carboxamidine,
N-[(4-chlorophenyl)sulfonyl]-N′-methyl-1-(4-chlorophenyl)-5-phenyl-4,5-dihydro-(1H)-pyrazole-3-carboxamidine,
N-[(4-Chlorophenyl)sulfonyl]-N′-methyl-1-(2,4-dichlorophenyl)-5-phenyl-4,5-dihydro-(1H)-pyrazole-3-carboxamidine,
N-{[(4-Trifluoromethyl)phenyl]sulfonyl}-N′-methyl-1-(2,4-dichlorophenyl)-5-phenyl-4,5-dihydro-(1H)-pyrazole-3-carboxamidine,
N-[(piperidin-1-yl)sulfonyl]-N′-methyl-1-(4-chlorophenyl)-5-phenyl-4,5-dihydro-(1H)-pyrazole-3-carboxamidine, and
N-[(Morpholin-4-yl)sulfonyl]-N′-methyl-1-(2,4-dichlorophenyl)-5-phenyl-4,5-dihydro-(1H)-pyrazole-3-carboxamidine.

### Claim 13

A method for treating eating disorders, obesity, juvenile obesity, and drug induced obesity in a patient in need thereof comprising:
administering an effective amount of at least one compound of formula (1), a tautomer, a stereoisomer, or an N-oxide thereof, or a salt or a hydrate of any of the foregoing:
wherein:
R1 and R2, which may be identical or different, are each chosen from
phenyls, thienyls and pyridyls, optionally substituted with 1, 2 or 3 substituents Y, which may be identical or different, chosen from branched or linear C1-3-alkyls and alkoxys, phenyls, hydroxys, chloro, bromo, fluoro, iodo, trifluoromethyl, trifluoromethylthio, trifluoromethoxy, methylsulfonyl, carboxyl, trifluoromethylsulfonyl, cyano, carbamoyl, sulfamoyl and acetyl, and
naphthyl;
X is chosen from (i) and (ii),
wherein:
R3 is chosen from hydrogen atoms and branched or linear C1-3 alkyl groups;
R4 is chosen from
branched or linear C1-8 alkyls and C3-8-cycloalkyl-C1-2-alkyl groups, branched or linear C1-8 alkoxys, C3-8 cycloalkyls, C5-10 bicycloalkyls, C6-10 tricycloalkyls, optionally comprising at least one heteroatom chosen from O, N, and S and optionally substituted with a group chosen from hydroxy groups, from 1 to 3 methyl groups, ethyl groups, and from 1 to 3 fluoro atoms,
phenoxy, benzyl, phenethyl and phenylpropyl groups, optionally substituted on the phenyl ring with 1, 2 or 3 substituents Y, which may be identical or different, chosen from branched or linear C1-3-alkyls and alkoxys, phenyls, hydroxys, chloro, bromo, fluoro, iodo, trifluoromethyl, trifluoromethylthio, trifluoromethoxy, methylsulfonyl, carboxyl, trifluoromethylsulfonyl, cyano, carbamoyl, sulfamoyl and acetyl,
pyridyl and thienyl groups, and
NR5R6 wherein:
R5 and R6, together with the nitrogen atom to which they are attached, form a saturated or unsaturated, monocyclic or bicyclic, heterocyclic group comprising from 4 to 10 ring atoms, wherein the heterocyclic group comprises one or two heteroatoms chosen from O, N, and S and wherein the heterocyclic group is optionally substituted with a group chosen from branched or linear C1-3 alkyls, phenyls, hydroxy, trifluoromethyl groups and fluoro atoms; or
R3 and R4, together with the nitrogen atom to which they are attached, form a saturated or unsaturated, monocyclic or bicyclic, heterocyclic group comprising from 4 to 10 ring atoms, wherein the heterocyclic group comprises one or two heteroatoms chosen from O, N, and S and wherein the heterocyclic group is optionally substituted with a group chosen from branched or linear C1-3 alkyls, phenyls, hydroxy, trifluoromethyl groups and fluoro atoms
R7 is chosen from
benzyl, phenyl, thienyl and pyridyl groups, optionally substituted on the aromatic ring with 1, 2, 3 or 4 substituents Y, which may be identical or different, chosen from branched or linear C1-3-alkyls and alkoxys, phenyls, hydroxys, chloro, bromo, fluoro, iodo, trifluoromethyl, trifluoromethylthio, trifluoromethoxy, methylsulfonyl, carboxyl, trifluoromethylsulfonyl, cyano, carbamoyl, sulfamoyl and acetyl,
C1-8 branched or linear alkyls, C3-8 alkenyls, C3-10 cycloalkyls, C5-10 bicycloalkyls, C6-10 tricycloalkyls and C5-8 cycloalkenyls,
naphthyl,
amino groups, and
C1-8dialkylamino groups, C1-8 monoalkylamino groups and saturated or unsaturated, monocyclic or bicyclic, heterocyclic groups having 4 to 10 ring atoms, wherein the heterocyclic group comprises 1 or 2 nitrogen atoms and wherein the heterocyclic group optionally comprises 1 heteroatom chosen from O and S and wherein the heterocyclic group is optionally substituted with anentity chosen from branched or linear C1-3 alkyls, phenyls, hydroxys, trifluoromethyls and fluoro atoms;
R8 is chosen from hydrogen atoms and branched or linear C1-3 alkyls;
R9 is chosen from
hydrogen atoms and branched or linear C1-8 alkyls, C3-8 cycloalkyls and C2-10 heteroalkyls, optionally substituted with a group chosen from keto groups, trifluoromethyl groups and fluoro atoms,
amino, hydroxy, phenoxy and benzyloxy groups
branched or linear C1-8 alkoxy groups, optionally substituted with an entity chosen from hydroxy groups, trifluoromethyl groups and fluoro atoms,
phenyl, benzyl, pyridyl, thienyl, pyridylmethyl and phenethyl groups wherein the aromatic rings are optionally substituted with 1, 2 or 3 of the substituents Y, which may be identical or different, chosen from branched or linear C1-3-alkyls and alkoxys, phenyls, hydroxys, chloro, bromo, fluoro, iodo, trifluoromethyl, trifluoromethylthio, trifluoromethoxy, methylsulfonyl, carboxyl, trifluoromethylsulfonyl, cyano, carbamoyl, sulfamoyl and acetyl, and
NR10R11 with the proviso when R8 is chosen from a hydrogen atom or a methyl group, and wherein
R10 and R11, which may be identical or different, are each chosen from C1-4 alkyls and C2-4 trifluoroalkyls or
R10 and R11, together with the nitrogen atom to which they are bonded, form a saturated or unsaturated heterocyclic group comprising from 4 to 8 ring atoms wherein the heterocyclic group comprises one or two atoms chosen from O, N, and S, and the heterocyclic group is optionally substituted with C1-2 alkyl groups; or
R8 and R9, together with the nitrogen atom to which they are bonded, form a saturated or unsaturated, monocyclic or bicyclic heterocyclic group comprising from 4 to 10 ring atoms, wherein the heterocyclic group comprises one or two atoms chosen from O, N, and S, keto groups and —SO2— groups, wherein the heterocyclic group is optionally substituted with C1-2 alkyls, hydroxys, phenyls, methylaminos, dimethylaminos, azetidinyls, pyrrolidinyls, piperidinyls and hexahydro-1H-azepinyls.

### Claim 14 (depends on 13)

The method according to claim 13, wherein:
R1 and R2, which may be identical or different, are each chosen from
phenyls, optionally substituted with 1, 2 or 3 substituents Y, which may be identical or different, chosen from branched or linear C1-3-alkyls and alkoxys, phenyls, hydroxys, chloro, bromo, fluoro, iodo, trifluoromethyl, trifluoromethylthio, trifluoromethoxy, methylsulfonyl, carboxyl, trifluoromethylsulfonyl, cyano, carbamoyl, sulfamoyl and acetyl, and
naphthyl;
R3 comprises a hydrogen atom;
R4 is chosen from
branched or linear C1-8 alkyls, branched or linear C1-8 alkoxys, and C3-8 cycloalkyls, optionally substituted with at least one group chosen from hydroxy groups, from 1 to 3 methyl groups, an ethyl group, and from 1 to 3 fluoro atoms,
phenoxy, -pyridyl and thienyl groups, and
NR5R6 wherein:
R5 and R6, together with the nitrogen atom to which they are attached, form a saturated or unsaturated, monocyclic or bicyclic, heterocyclic group comprising from 4 to 10 ring atoms, wherein the heterocyclic group comprises one or two heteroatoms chosen from O, N, and S; or
R3 and R4, together with the nitrogen atom to which they are attached, form a saturated or unsaturated, monocyclic or bicyclic, heterocyclic group comprising from 4 to 10 ring atoms, wherein the heterocyclic group comprises one or two heteroatoms chosen from O, N, and S and wherein the heterocyclic group is optionally substituted with a group chosen from methyl groups, hydroxy groups, trifluoromethyl groups and fluoro atoms;
R7 is chosen from
phenyl groups, optionally substituted on the aromatic ring with 1, 2, 3 or 4 substituents Y, which may be identical or different, chosen from branched or linear C1-3-alkyls and alkoxys, phenyls, hydroxys, chloro, bromo, fluoro, iodo, trifluoromethyl, trifluoromethylthio, trifluoromethoxy, methylsulfonyl, carboxyl, trifluoromethylsulfonyl, cyano, carbamoyl, sulfamoyl and acetyl,
C1-8 branched or linear alkyls, C3-10 cycloalkyls, and C5-10 bicycloalkyls,
naphthyl,
amino groups, and
C1-8 dialkylamino groups, C1-8 monoalkylamino groups and saturated or unsaturated, monocyclic or bicyclic, heterocyclic groups having from 4 to 10 ring atoms, wherein the heterocyclic group comprises 1 or 2 nitrogen atoms and wherein the heterocyclic group optionally comprises 1 heteroatom chosen from O and S and wherein the heterocyclic group is optionally substituted with branched or linear C1-3 alkyls and hydroxys;
R8 is chosen from hydrogen atoms and branched or linear C1-3 alkyls;
R9 is chosen from
hydrogen atoms and branched or linear C1-4 alkyls or C3-8 cycloalkyls, optionally substituted with a group chosen from trifluoromethyl groups and fluoro atoms,
amino, hydroxy, phenoxy and benzyloxy groups,
branched or linear C1-8 alkoxy groups,
phenyl groups wherein the aromatic rings are optionally substituted with 1, 2 or 3 of the substituents Y, which may be identical or different, chosen from branched or linear C1-3-alkyls and alkoxys, phenyls, hydroxys, chloro, bromo, fluoro, iodo, trifluoromethyl, trifluoromethylthio, trifluoromethoxy, methylsulfonyl, carboxyl, trifluoromethylsulfonyl, cyano, carbamoyl, sulfamoyl and acetyl, and
NR10R11 with the proviso when R8 is chosen from a hydrogen atom or a methyl group, and wherein
R10 and R11, which may be identical or different, are each chosen from C1-4 alkyls and C2-4 trifluoroalkyls or
R10 and R11, together with the nitrogen atom to which they are bonded, form a saturated or unsaturated heterocyclic group comprising from 4 to 8 ring atoms wherein the heterocyclic group comprises one or two atoms chosen from O, N, and S; or
R8 and R9, together with the nitrogen atom to which they are bonded, form a saturated or unsaturated, monocyclic or bicyclic heterocyclic group comprising from 4 to 10 ring atoms, wherein the heterocyclic group comprises one or two atoms chosen from O, N, and S, keto groups and —SO2— groups.

### Claim 15 (depends on 13)

The method according to claim 13, wherein the formula (1) compound is chosen from
N-(piperidin-1-yl)-1-(4-chlorophenyl)-5-phenyl-4,5-dihydro-(1H)-pyrazole-3-carboxamide,
N-(Piperidin-1-yl)-5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4,5-dihydro-(1H)-pyrazole-3-carboxamide,
N-(Piperidin-1-yl)-1-(2,4-dichlorophenyl)-5-phenyl-4,5-dihydro-(1H)-pyrazole-3-carboxamide,
N-(Cyclohexyl)-1-(2,4-dichlorophenyl)-5-phenyl-4,5-dihydro-(1H)-pyrazole-3-carboxamide,
N-[(4-fluorophenyl)sulfonyl]-1-(4-chlorophenyl)-5-phenyl-4,5-dihydro-(1H)-pyrazole-3-carboxamidine,
N-[(4-fluorophenyl)sulfonyl]-1-(2,4-dichlorophenyl)-5-phenyl-4,5-dihydro-(1H)-pyrazole-3-carboxamidine,
N-[(4-chlorophenyl)sulfonyl]-N′-methyl-1-(4-chlorophenyl)-5-phenyl-4,5-dihydro-(1H)-pyrazole-3-carboxamidine,
N-[(4-Chlorophenyl)sulfonyl]-N′-methyl-1-(2,4-dichlorophenyl)-5-phenyl-4,5-dihydro-(1H)-pyrazole-3-carboxamidine,
N-{[(4-Trifluoromethyl)phenyl]suifonyl}-N′-methyl-1-(2,4-dichlorophenyl)-5-phenyl-4,5-dihydro-(1H)-pyrazole-3-carboxamidine,
N-[(piperidin-1-yl)sulfonyl]-N′-methyl-1-(4-chlorophenyl)-5-phenyl-4,5-dihydro-(1H)-pyrazole-3-carboxamidine, and
N-[(Morpholin-4-yl)sulfonyl]-N′-methyl-1-(2,4-dichlorophenyl)-5-phenyl-4,5-dihydro-(1H)-pyrazole-3-carboxamidine.

### Claim 16 (depends on 13)

The method according to claim 13, further comprising administering at least one lipase inhibitor.

### Claim 17 (depends on 16)

The method according to claim 16, wherein the at least one lipase inhibitor is chosen from orlistat and lipstatin.